Daniels David J, Lenard Natalie R, Etienne Chris L, Law Ping-Yee, Roerig Sandra C, Portoghese Philip S
Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19208-13. doi: 10.1073/pnas.0506627102. Epub 2005 Dec 19.
Given the mounting evidence for involvement of delta opioid receptors in the tolerance and physical dependence of mu opioid receptor agonists, we have investigated the possible physical interaction between mu and delta opioid receptors by using bivalent ligands. Based on reports of suppression of antinociceptive tolerance by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-antagonist (MDAN) series] that contain different length spacers, and pharmacophores derived from NTI and the mu agonist oxymorphone, have been synthesized and evaluated by intracerebroventricular (i.c.v.) administration in the tail-flick test in mice. In acute i.c.v. studies, the bivalent ligands functioned as agonists with potencies ranging from 1.6- to 45-fold greater than morphine. In contrast, the monovalent mu agonist analogues were substantially more potent than the MDAN congeners and were essentially equipotent with one another and oxymorphone. Pretreatment with NTI decreased the ED(50) values for MDAN-19 to a greater degree than for MDAN-16 but had no effect on MDAN-21. Chronic i.c.v. studies revealed that MDAN ligands whose spacer was 16 atoms or longer produced less dependence than either morphine or mu monovalent control MA-19. On the other hand, both physical dependence and tolerance were suppressed at MDAN spacer lengths of 19 atoms or greater. These data suggest that physical interaction between the mu and delta opioid receptors modulates mu-mediated tolerance and dependence. Because MDAN-21 was found to be 50-fold more potent than morphine by the i.v. route (i.v.), it offers a previously uncharacterized approach for the development of analgesics devoid of tolerance and dependence.
鉴于越来越多的证据表明δ阿片受体参与μ阿片受体激动剂的耐受性和身体依赖性,我们通过使用双价配体研究了μ和δ阿片受体之间可能的物理相互作用。基于δ拮抗剂纳曲吲哚(NTI)对抗伤害感受耐受性的抑制报道,已经合成了包含不同长度间隔基以及源自NTI和μ激动剂羟吗啡酮药效基团的双价配体[μ-δ激动剂-拮抗剂(MDAN)系列],并通过脑室内(i.c.v.)给药在小鼠甩尾试验中进行了评估。在急性i.c.v.研究中,双价配体发挥激动剂作用,效力比吗啡高1.6至45倍。相比之下,单价μ激动剂类似物比MDAN同系物效力更强,彼此之间以及与羟吗啡酮基本等效。用NTI预处理使MDAN-19的ED(50)值降低的程度大于MDAN-16,但对MDAN-21没有影响。慢性i.c.v.研究表明,间隔基为16个原子或更长的MDAN配体产生的依赖性比吗啡或μ单价对照MA-19都要小。另一方面,当MDAN间隔基长度为19个原子或更长时,身体依赖性和耐受性均受到抑制。这些数据表明,μ和δ阿片受体之间的物理相互作用调节了μ介导的耐受性和依赖性。由于发现MDAN-21通过静脉内(i.v.)途径的效力比吗啡高50倍,它为开发无耐受性和依赖性的镇痛药提供了一种前所未有的方法。